Cardiac stem cell research still active

January 2009
CMAJ: Canadian Medical Association Journal;1/6/2009 Conference Reports, p7
Academic Journal
The article offers information on the updates and developments of cardiac clinical trials involving stem cells for better management of acute myocardial infarction (AMI) and congestive heart failure (CHF). It is mentioned that stem cell research to date has provided future prospects in cardiology. Several clinical trials on AMI and CHF are reviewed.


Related Articles

  • Stem-Cell Transplantation in Myocardial Infarction: A Status Report. Lee, Michael S.; Makkar, Raj R. // Annals of Internal Medicine;5/4/2004, Vol. 140 Issue 9, p729 

    Myocardial infarction is the leading cause of congestive heart failure and death in the industrialized world. Current therapy is limited in preventing the progression of ventricular remodeling and congestive heart failure. Recent interest has focused on stem cells, which are undifferentiated and...

  • Bone marrow-derived stem cells for ischemic hearts. Kocher, Alfred A. // Wiener Klinische Wochenschrift;2003, Vol. 115 Issue 3/4, p77 

    This article presents information on bone marrow-derived stem cells for ischemic hearts. Congestive heart failure remains a major public health problem. As new modalities have emerged which have enabled significant reduction in early mortality from acute myocardial infarction there has been a...

  • CARRESS-HF: Ultrafiltration Not Superior to Pharmacologic Therapy in the Treatment of Acute Heart Failure. Buckley, Rita // MD Conference Express;Dec2012, p24 

    The article discusses the findings from the Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF) trial by Bradley A. Bart. The study aims to test whether ultrafiltration was superior to stepped pharmacologic therapy for the treatment of patients with acute decompensated...

  • Intensive statin therapy reduces cardiovascular events.  // Australian Journal of Pharmacy;Mar2011, Vol. 92 Issue 1090, p76 

    The article offers information on the two studies that differentiate intensive statin regimens with placebo and low dose statin therapy on major cardiovascular events. It highlights the significance of low-density lipoprotein (LDL) as triggering factor for coronary heart disease. It notes that...

  • In-hospital complications after invasive strategy for the management of Non STEMI: women fare as well as men. Berthillot, Caroline; Stephan, Dominique; Chauvin, Michel; Roul, Gerald // BMC Cardiovascular Disorders;2010, Vol. 10, p31 

    Background: To analyze the in-hospital complication rate in women suffering from non-ST elevation myocardial infarction treated with percutaneous coronary intervention (PCI) compared to men. Methods: The files of 479 consecutive patients (133 women and 346 men) suffering from a Non STEMI (Non...

  • Fish Oil Plus Statins. Crawford, Michael H. // Clinical Cardiology Alert;Jun2007, Vol. 26 Issue 6, p41 

    Secondary prevention trials have demonstrated reduced coronary heart disease (CHD) deaths in post myocardial infarction (MI) patients who consume fish or fish oil, but no prospective randomized primary prevention trials have been done. Thus, the Japan Eicosapentaenoic acid (EPA) Lipid...

  • Human Embryonic Stem Cell-Derived Cardiomyocytes for Heart Therapies. Chung Wah Siu; Moore, Jennifer C.; Li, Ronald A. // Cardiovascular & Haematological Disorders - Drug Targets;Jun2007, Vol. 7 Issue 2, p145 

    Cardiovascular diseases remain the leading cause of mortality and morbidity worldwide. Despite substantial improvements in acute management, survivors of myocardial infarction often progress to heart failure. Since adult cardiomyocytes (CMs) do not regenerate, their loss permanently compromises...

  • Hypothesis: atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease. Novela, Cristina; Hennekens, Charles H. // Journal of Cardiovascular Pharmacology & Therapeutics;Mar2004, Vol. 9 Issue 1, p61 

    The results of numerous long-term, randomized trials show that statins significantly decrease the risks of myocardial infarction, stroke, and vascular death as well as total mortality. The benefits of statins on cardiovascular disease in patients who are not experiencing acute coronary syndromes...

  • Preprocedural statin therapy reduces the risk and extent of cardiac biomarker release following percutaneous coronary intervention. Veselka, Josef; Proch�zkov�, ��rka; Duchonov�, Radka; Homolov�, Ingrid; Tesar, David; Bybee, Kevin A. // Heart & Vessels;May2006, Vol. 21 Issue 3, p146 

    This study evaluates the association between statin therapy in patients treated by percutaneous coronary intervention (PCI) for stable angina pectoris and postinterventional myocardial injury with subsequent long-term clinical outcome. Prospectively collected data on 400 consecutive patients...


Read the Article


Sign out of this library

Other Topics